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Key Points/Highlights: 
1. Genetic heterogeneity within renal cell carcinoma is of growing interest due to its 
potential effects on therapeutic options and drug efficacy. 
2. While several hallmark truncal molecular aberrations are well known, recent studies have 
identified spatially heterogenous, subclonal mutations which may contribute to tumor 
progression and the relatively poor efficacy of current treatment options. 
3. The importance of multifocal tumor sampling to appropriately assess the extent of 
transcriptomic and genomic profile is significant, as single biopsy sampling is likely 
insufficient. 
4. While pathways associated with traditional truncal molecular aberrations (e.g. VHL) 
remain fundamental targets for treatment in renal cell carcinoma, a growing 
understanding of subclonal mutations and intratumoral heterogeneity may offer new 
options for treating clinicians and their patients. 
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Abstract 
The topic of tumoral heterogeneity at the genetic level has become relevant in various solid 
origin tumors, particularly in an age of targeted treatment. Renal cell carcinoma is known for a 
sizable subset of tumors presenting at advanced clinical stage, further highlighting the 
importance and timeliness of this topic and its potential impact on adjuvant therapy. Recent 
studies have shown that molecular aberrations in renal cell carcinoma go beyond known truncal 
mutations and that downstream, subclonal aberrations are spatially heterogenous. Intratumoral 
heterogeneity as well as the differences in the molecular landscape between primary and 
metastatic lesions remains underappreciated, often due to inadequate sampling of tumors. The 
overall effect of these factors on the efficacy of current treatment options in renal cell carcinoma 
remains unknown; however, several recent studies have attempted to elucidate the extent and 
impact genetic heterogeneity in renal cell neoplasia may have on patient treatment and prognosis.   
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1. Introduction 
The topic of tumoral heterogeneity is not unique to renal cell carcinoma (RCC). Various 
studies have evaluated intratumoral heterogeneity in malignancies involving the pancreas, breast, 
lung, brain, and gynecologic tract by different molecular modalities including chromosomal 
mutational and copy number analyses[1-5]. RCC continues to be associated with a relatively 
poor prognosis given that 20 to 30% of cases present with metastatic disease and subsequent 
poor five-year survival (5 to 10%)[6]. In the setting of adjuvant therapy in RCC, an 
overwhelming majority of agents show modest to poor results in their effects limiting disease 
progression and improving overall survival[7-9]. Acquisition of intratumoral heterogeneity as a 
tumor evolves has been postulated as a contributing factor[10]. 
 
2. Morphologic and Molecular Intratumoral Heterogeneity 
Even prior to analysis at the molecular level, morphologic heterogeneity within RCCs has 
been extensively studied[11]. While it may have been reasonable to presume differentiation of 
tumors by routine light microscopy should correlate with molecular heterogeneity, this may not 
be the case. For example, in studies comparing conventional carcinoma morphologies with 
sarcomatoid differentiation, preservation of truncal mutations as well as concordant allelic loss 
and X-chromosome inactivation have been shown despite obvious morphologic differences[12]. 
Conversely, a study by Ito el al. identified more complex genetic profiles and increased 
chromosomal aberrations in sarcomatoid RCC when compared to conventional clear cell, 
papillary, or chromophobe RCCs[13]. Various methods have been used to assess for intratumoral 
variability at the molecular level, including assessment of copy number aberrations[14]. While a 
majority of studies investigating tumoral heterogeneity have focused on clear cell RCC, studies 
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evaluating papillary and chromophobe RCCs have also been performed. In a study by Brunelli et 
al, chromophobe RCC with sarcomatoid features demonstrated unique and increased 
chromosomal changes that differed from those identified in conventional chromophobe RCC. 
Interestingly, the same study found that primary and metastatic lesions shared the same genetic 
pattern[15,16].  
 
3. Truncal versus Subclonal Molecular Aberrations in Intratumoral Heterogeneity  
Tumor progression following truncal-type events (e.g. chromosome 3p loss in clear cell 
RCC) is comprised of the acquisition of subclones[14]. von Hippel-Lindau (VHL) serves as 
tumor suppressor gene (predominantly through the hypoxia-inducible pathway[HIF]) is located 
within chromosome 3p[17]. Other tumor suppressor genes, such as SETD2, PBRM1, and BAP1 
are notably located on the short arm of chromosome 3p (all within a 50-Mb region)[18-20]. 
Mutations in the mammalian target of rapamycin (mTOR) pathway have been reported to occur 
downstream from VHL mutations/3p loss[21,22]. It is also postulated that these mTOR 
alterations have some effect on the HIF pathway as well[23-25]. VHL function serves an 
important role in cellular proliferation, angiogenesis, and preservation of epithelial 
differentiation[17]. In PRCC, besides polysomies (chromosome 7/17), mutations have been 
identified including MET (on chromosome 7), NF2 (in the Hippo signaling pathway), and PNKD 
(paroxysmal nonkinesigenic dyskinesia)[26]. While PRCC types 1 and 2 have been shown to be 
genetically and clinically distinct, a substantial majority show chromosomal gains of 7 and 
17[27,28]. Chromophobe renal cell carcinoma (chRCC) is most notably associated with loss of 
chromosomes 1, 2, 6, 10, 13, 17, and 21[29]. Lesser known chRCC mutations, including Tp53, 
PTEN, and FAAH2 have also been identified[13,15,29-31]. 
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In the distinction between linear progression of tumor evolution and branched and/or 
braided evolution patterns, the acquisition of mTOR pathway mutations downstream from 
truncal mutations likely explains the success with tyrosine kinase-targeting therapeutic 
agents[32] (Figure 1). The persistence of preserved truncal mutations (e.g. VHL, trisomy 7/17, 
etc.) despite the intratumoral heterogeneity among subclonal mutations has supported the 
hypothesis of a “braided progression” of molecular heterogeneity. In this hypothesis, the truncal 
mutation serves as a possible source for all subsequent mutations, which can be unique, rather 
than the previously thought linear or parallel-type progression of tumor molecular 
aberrations[33]. The “braided” model also hypothesizes that spatially heterogenous mutations 
may happen at different points in time but the overall genomic profile inevitably becomes 
similar[34]. 
One key challenge when assessing the role of intratumoral heterogeneity is the balance 
between acquired heterogeneity, typically through a subclonal population, while also assessing 
for the preservation of truncal events in all areas of the tumor[35]. Intratumoral heterogeneity 
likely explains how despite “classic” truncal mutations being seen in various RCC subtypes, 
individual tumors may behave very differently in spite of these common molecular 
aberrations[10]. While Gerlinger et al. found previously reported VHL mutations as well as 
chromosome 3p deletions in all clear cell RCCs in their study, mutations in pathways such as 
mTOR, BAP1, PTEN, p53, and SETD2 were identified solely in subclonal populations and were 
spatially heterogenous[36]. Despite acquired subclonal populations in varying tumor regions, 
Kouba et al. have demonstrated the concordance of truncal mutational status in primary and 
metastatic sites, even in the setting of sarcomatoid differentiation[6]. It remains unclear if the 
preservation of truncal mutations in residual disease or metastatic sites serves as an indication for 
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targeted treatment or if this aggressive behavior is unrelated to the tumor still baring these 
truncal mutations[36,37]. Additionally, it raises further questions whether assessing the 
molecular landscape of the primary tumor serves any benefit in the setting of metastatic disease. 
Since the development of metastases is associated with a poor prognosis, some have postulated 
whether molecular analysis for treatment options should focus entirely on the genetic landscape 
of the metastatic disease[36]. 
The spatial separation of subclones and particularly apparent isolation of various 
subclonal driver mutations supports the argument that RCCs can undergo unique evolutionary 
pathways simultaneously, despite arising from the same truncal mutation[36] (Figure 2). Gulati 
et al. have demonstrated significant intratumoral heterogeneity, particularly in subclones 
harboring distinct somatic copy number aberrations and driver mutations, within different tumor 
foci as well as with matched metastatic sites[38]. The apparent ability of tumors to develop 
diverse and spatially unique subclonal changes could explain how RCCs adapt to external 
pressures, such as immune responses, hypoxia, or even therapeutic intervention[39].  
 
4. Tumor Sampling 
Numerous studies have identified that single biopsy assessment for molecular aberrations 
is insufficient, particularly in assessment for use of certain targeted therapeutic agents as well as 
assessment for known aberrations with prognostic significance [6,10,12,14,36,37]. Furthermore, 
the importance of multifocal sampling to appropriately assess the extent of transcriptomic and 
overall genomic profile of tumors cannot be understated, as single biopsy sampling is 
insufficient[38] (Figure 3A). Gerlinger et al. notably applied exome sequencing, analysis for 
chromosome aberrations, and DNA ploidy profiling to a cohort of RCC primary and metastatic 
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lesions to assess the genetic landscape of these tumors[10] (Figure 3B). Interestingly, the 
authors embarked on a multifocal approach, to not only compare tumors between patients, but to 
in fact, compare different regions of the same tumor. This multifocal approach using various 
molecular analysis modalities translated to a seminal paper in assessing tumor heterogeneity in 
RCC[10]. While focal sampling (e.g. single biopsy) is suboptimal in assessment of tumor 
heterogeneity, even multifocal exome-sequencing may be suboptimal as differences in 
noncoding regions may be missed[40]. Early findings in many of these studies are promising, but 
the molecular landscape in RCC appears to be vastly underappreciated even with multifocal 
sampling. 
Advances in sampling have entertained the possibility of non-invasive assessment of 
tumoral genetic landscape via circulating tumor DNA (ctDNA)[41,42] . Previously, ctDNA 
assessment by simple peripheral blood sampling has shown promise in assessing molecular 
aberrations in other solid tumors organ and hematopoietic malignancies. Pal et. al have recently 
published data on ctDNA findings prior to and then following treatment with systemic 
therapeutic agents in the setting of metastatic RCC[43]. While the data is limited, it does offer a 
potentially novel alternative to conventional core biopsy/needle aspiration sampling, which has 
proved to be suboptimal in many cases. 
 
5. Treatment Implications due to Intra- and Intertumoral Molecular Heterogeneity  
While variant histology within RCC may be derived from the same cell of origin, 
acquisition of unique genetic aberrations within subclonal cell populations may still harbor 
obstacles to therapeutic treatment despite preservation of truncal mutations[12]. Adjuvant 
therapy in RCC has typically been reserved for metastatic disease; however, identification of 
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molecular aberrations that may predict metastatic potential could have significant influence on 
treatment plans[9,35].  Tyrosine kinase inhibitors that target the VEGF pathways include 
sunitinib, sorafenib, pazopanib, axitinib, levatinib, and cabozantinib and remain first line therapy 
in metastatic RCC[8,34,44-49]. Bevacizumab (Avastin) is a pure anti-VEGF therapy which is 
different from tyrosine kinase inhibitors that indirectly target the VEGF pathway and related 
proteins[50,51]. Currently, mTOR inhibitors, including everolimus and temsirolimus, are second 
line therapy; however, have been used as 1st line therapy in poor risk patients[34]. With the 
advent of new immunotherapeutic options and the persistence of anti-angiogenic agents as first 
choice, mTOR inhibitors have trended towards becoming third line therapy[52].Some evidence 
has been shown to suggest therapeutic agents used to treat CCRCC, including sunitinib, 
sorafenib, and mTOR inhibitors such as everolimus and temsirolimus, could also show efficacy 
in other RCC subtypes including PRCC and chRCC.  Of note, PRCC Type 2 has shown 
enrichment of CCRCC-associated pathways including, mTOR, VEGF, and HIF-alpha[28]. In 
patients who initially showed response with mTOR inhibitors (e.g. everolimus and 
temsirolimus), retrospective tumor analysis highlighted that mutations in the mTOR pathway 
were spatially heterogenous, which supported the need for multifocal sampling of tumors[35]. 
Foretinib, which is a mutikinase agent targeting MET, AXL, and other receptors have 
been used in patients with PRCC in lieu of CCRCC therapies[29]. Foretinib appears to benefit 
patients with germline MET mutations compared to all PRCC patients[53]. Resistance to first 
line VEGF inhibitors has been attributed to mutations in tyrosine kinase pathways (e.g. MET or 
AXL). Combination therapy or use of drugs that target both VEFG and MET pathways (e.g. 
cabozantinib) would in theory address this issue, but toxicity with agents remains a serious issue 
in RCC treatment[54]. Currently, there are no readily accepted chemotherapeutic or anti-
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angiogenic drugs specific for treating RCC with sarcomatoid differentiation; however, theories 
behind the efficacy of anti-angiogenic agents, particularly anti-VEGF drugs, in sarcomatoid RCC 
include the increased proliferation index and persistent HIF-pathway expression in these 
tumors[25,55]. 
Immunotherapy has previously been used in treating RCC, most notably interferon-alpha 
and interleukin-2[56]. These treatments had severe adverse effects and minimal efficacy. 
Programmed cell death protein 1 (PD-1) and its ligand (PD-L1) being expressed in a majority of 
RCC has resurfaced interest in using immunotherapy as treatment[54]. Interest in therapeutic 
options using anti-PD-1 immune checkpoint inhibitors, such as nivolumab, has been noted in 
RCC, following success in other solid tumors, such as lung adenocarcinoma[57-59]. Initially, 
treatment with immune checkpoint inhibitors was reserved for refractory patients who had tumor 
progression after failure with fist- and second-line therapy regimens[60]. With subsequent 
studies, use of nivolumab in patients with disease progression in metastatic RCC has shown 
some success in lesion stabilization and even tumor reduction[59]. The introduction of new 
therapeutic options, particularly with immunotherapies (e.g targeting PD-1 and CTLA-4 
pathways) has raised arguments for use and second or third-line options in patients with resistant 
metastatic RCC[52]. Current trends show that improved data likely supports immunotherapies as 
second line treatment in metastatic RCC, replacing everolimus [61]. 
Specific dosing and possibility for combination therapy with therapeutic agents are 
currently being studied[57]. Combination therapy as first line treatment is not recognized in any 
current guidelines; however, several options in the setting of treatment resistance have been 
proposed. Lenvatinib (a multi-target tyrosine kinase inhibitor) has been suggested for use in 
combination with everolimus in patients with metastatic RCC who have developed resistance to 
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more common first-line tyrosine kinase inhibitors [62]. Benefits using newer immunotherapeutic 
agents in combination with first line antiangiogenic agents remain unclear and currently data is 
lacking to support the vast expense associated with this treatment option [62]. 
Unfortunately, overall efficacy of immune checkpoint inhibitors in RCC has been mild at 
best, with some arguing that response rates do not correlate with levels of PD-L1/PD-1 
expression[61,63,64]. Combination with another immunotherapy, ipilimumab (a CTLA-4 
inhibitor of cytotoxic T cells), is also currently being explored as a treatment option in metastatic 
RCC[65-67]. Currently, several late stage clinical trials may offer clinicians more information 
combination treatment options. Newer anti-PD1/PD-L1 agents, such as Atezolizumab and 
Pembrolizumab, are being tested in combination with anti-VEGF agents to see how patients 
respond compared to traditional first-line therapy with sunitinib [68,69]. Additionally, in a 
possible shift from antiangiogenic based treatment, the combination of nivolumab and 
ipilimumab could provide the first viable immunotherapy-only as first-line therapy in metastatic 
RCC [54,68,70]. Progressive understanding of the immunotherapeutic landscape, new agents, 
and potential combination therapies are positive signs in treatment of high-stage RCC. 
Unfortunately, the limited number of patients showing clinical (and lasting) benefit with 
treatment and the immense cost has posed difficult challenges for patients and treating clinicians 
[71]. Potential benefit from combination therapy using tradition first-line agents such as 
antiangiogenic drugs could bridge treatment regiments until further progress is made with newer 
targeted agents [72]. 
The complexities of the immunophenotypic landscape of RCC poses similar challenges 
in treatment as previously seen with chemotherapeutic/anti-angiogenic agents[66]. Of note, the 
higher number of mutations for PD-L1 identified in metastases could explain efficacy seen when 
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using immunotherapeutic agents in this setting, but further studies are required[56,73,74]. 
Analysis of the genomic landscape in RCC patients status post immunotherapy treatment 
remains significantly limited. The majority of data currently available comes from the melanoma 
literature, where immunotherapy has shown high response rate but also high toxicity in patients, 
particularly in combination therapy with PD-1 and CTLA-4 inhibitors [65,75,76]. The proposed 
synergistic responses of these two agents, one by activating antigen-specific T cells (e.g  anti-
CTLA4 pathway) and the other by removing inhibition on T cells to attack cancer cells (e.g. anti-
PD1 pathway)shows great promise in RCC[77,78]. Unfortunately, these checkpoint inhibitors 
are associated with high cost and significant toxicity and currently benefit only a small subset of 
all patients [79]). 
An additional challenge facing patients is the genomic landscape variability between 
treatment-naive tumor samples, versus metastatic tumor samples, versus tumor post-treatment 
sampling (either antiangiogenic agents or immunotherapy)[80]. In the short term, identifying 
patients who will actually benefit from these therapies remains a key priority [72]). A study by 
Chevrier et al. using mass spectrometry to profile the immunologic microenvironment in ccRCC 
has provided a strong foundation to guide further development of potential biomarkers and 
targets [66]. Despite variable modalities for assessing PD-1/PD-L1 expression in RCC, 
inherently positive expression of PD-1/PD-L1 does not always correlate with treatment efficacy. 
Resistance to immunotherapeutic agents may, in fact, be secondary to non-immunogenic factors 
such as metabolic factors which block attacking immune cells or possibly improve cancel cell 
fitness [81]. 
Additionally, subclones that may be responsible for therapeutic resistance could possibly 
be clustered in certain un- or under-sampled tumor regions or of low enough frequency to evade 
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detection with single or possibly even multi-site sampling[14]. Determining the effectiveness of 
targeting ubiquitous truncal driver mutations (e.g. VHL, trisomy 7/17) relies heavily on the 
tumor’s dependence on them for survival; however, if subclonal drivers in fact are the cause of 
tumor progression, the relative ineffectiveness of many drugs could be explained[36]. 
Furthermore, this would make the relative preservation of truncal mutations in metastatic sites 
irrelevant, as they are no longer the factors driving disease advancement. 
Increased intratumoral heterogeneity accompanied with increased copy number variations 
(genomic instability) has been hypothesized to possibly favor improved overall outcome. Andor 
et al. have argued this could be secondary increased immune response or the possibility of 
generating defective daughter cells[40]. It may be that the same genomic instability driving 
tumor progression and poor outcomes could also have a negative effect if proliferating tumor 
cells are nonviable[36]. Despite the obvious morphologic, immunophenotypic, and now 
molecular differences in various RCC subtypes, the treatment approach is essentially the same 
regardless. Regardless of spatial heterogeneity seen in RCC, the relative preservation of truncal 
driver mutations will likely continue to serve as optimal targets for treatment therapeutic agents 
until the role of subclonal populations in tumor progression is better understood[7-10,36,37]. 
 
6. Conclusion 
 The concept of intra- and intertumoral genetic heterogeneity remains a timely yet 
underappreciated topic in renal cell carcinoma. While traditional truncal molecular aberrations 
have been well-known for some time, particularly in clear cell and papillary RCCs, recent 
findings have shown that these mutations may not be optimal targets for therapeutic treatment in 
advanced disease. The most significant challenge remains that despite these frequent and 
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apparently ubiquitous alterations in VHL-VEGF and mTOR pathways, overall efficacy of 
targeted drugs does not seem to correlate with mutational status. Further study of the molecular 
landscape in renal cell carcinoma, particularly in acquired subclonal aberrations and driver 
mutations, may provide invaluable information for future treatment options and overall 
prognosis.  
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Figure Legends 
Figure 1: Traditional thinking in terms of tumor evolution has changed in recent years with the 
linear model (A) now being replaced with a “braided” evolution pattern (B). In the “braided” 
pattern, while mutations such as von Hippel Lindau or loss of chromosome 3p may be truncal 
events, subsequent mutations likely interact and persistence of truncal mutations is possible. 
 
Figure 2: The spacial heterogeneity of subclones acquired in renal cell neoplasia remains 
unclear, despite several hypotheses. The interaction of subclones in malignant renal tumors could 
be complete independence via geographic separation (A), survival of the strongest subclones via 
competition (B), or an interactive-symbiotic relationship (C).  
 
Figure 3: Various studies have argued that single biopsy sampling of renal tumors is likely 
inadequate to assess the genetic heterogeneity. Furthermore, concordance and/or discordance of 
molecular aberrations between metastatic disease and primary tumors may offer insights into 
efficacy of various therapeutic treatment options. 
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